Athero-Blocker – New peptides for the prevention and treatment of atherosclerosis
Scientists at the RWTH Aachen have identified new
peptides which can be used for the prevention of atherosclerosis or in the treatment of related cardiovascular diseases. It is known that adherent activated platelets secrete chemoattractants, such as the chemokines PF4 and RANTES, which are responsible for monocyterecruitment. Receptor-blocking experiments and studies with knock-out mice indicated that RANTES signals contribute to intimal hyperplasia and macrophage infiltration in models of restenosis. Moreover, it plays an important role in the initiation and maintenance of atherosclerosis. Athero-Blocker is specifically targeting the interaction between the chemokines RANTES and PF4. It can thereby abrogate the proatherogenic enhancement of monocyte recruitment caused by this interaction. A good efficacy of Athero-Blocker has been demonstrated in in vitro experiments, in cell based test systems and in mouse models in vivo.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
